{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:07:37Z","timestamp":1784826457655,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.gastro.2026.02.016","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:12:50Z","timestamp":1771981970000},"page":"9-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Immunotherapy for DNA Mismatch Repair-Deficient Colon and Rectal Cancers"],"prefix":"10.1053","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-1000","authenticated-orcid":false,"given":"Frank A.","family":"Sinicrope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.02.016_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/cancers13020300","article-title":"Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2026.02.016_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-18-0856","article-title":"Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate","volume":"26","author":"Willis","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.02.016_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib4","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review","volume":"9","author":"Emiloju","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2026.02.016_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00262-025-03980-x","article-title":"Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy","volume":"74","author":"Landre","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.gastro.2026.02.016_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1053\/j.gastro.2026.02.016_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andre","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.02.016_bib8","article-title":"Updates in metastatic colorectal cancer","volume":"23","author":"Venook","year":"2025","journal-title":"J National Comprehensive Cancer Netw"},{"key":"10.1053\/j.gastro.2026.02.016_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.02.016_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","article-title":"Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer","volume":"394","author":"Sinicrope","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.02.016_bib13","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20230098","article-title":"The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer","volume":"96","author":"Platt","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1053\/j.gastro.2026.02.016_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112329","article-title":"Prediction of histopathology in colon cancer by multidetector computed tomography stratified by tumour side and microsatellite status: a national register study","volume":"191","author":"Casarin","year":"2025","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.gastro.2026.02.016_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.gastro.2026.02.016_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib17","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.02.016_bib19","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib20","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.016_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103929","article-title":"Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study","volume":"9","author":"Tosi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1053\/j.gastro.2026.02.016_bib22","article-title":"Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience","volume":"11","author":"Emiloju","year":"2025","journal-title":"ESMO Open"},{"key":"10.1053\/j.gastro.2026.02.016_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105516","article-title":"Neoadjuvant immunotherapy for nonmetastatic dMMR\/MSI colon cancer: a real-world retrospective AGEO study","volume":"10","author":"Lemaire","year":"2025","journal-title":"ESMO Open"},{"key":"10.1053\/j.gastro.2026.02.016_bib24","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2026.02.016_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/DCR.0000000000001135","article-title":"Can endorectal ultrasound, MRI, and mucosa integrity accurately predict the complete response for mid-low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center","volume":"61","author":"Liu","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2026.02.016_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jmri.28426","article-title":"Rectal MRI interpretation after neoadjuvant therapy","volume":"57","author":"Horvat","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"10.1053\/j.gastro.2026.02.016_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2024.01.016","article-title":"Genomic landscape of Lynch syndrome colorectal neoplasia identifies shared mutated neoantigens for immunoprevention","volume":"166","author":"Bolivar","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.016_bib28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b\/2 trial","volume":"32","author":"D'Alise","year":"2026","journal-title":"Nat Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526001484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526001484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:31:06Z","timestamp":1784824266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508526001484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0016508526001484"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.02.016","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Immunotherapy for DNA Mismatch Repair-Deficient Colon and Rectal Cancers","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}